{"id":22714,"date":"2026-07-24T16:46:23","date_gmt":"2026-07-24T12:46:23","guid":{"rendered":"https:\/\/medscriptum.org\/?p=22714"},"modified":"2026-07-26T19:44:56","modified_gmt":"2026-07-26T15:44:56","slug":"fda-approves-zidesamtinib-for-the-treatment-of-ros1-positive-non-small-cell-lung-cancer-nsclc","status":"publish","type":"post","link":"https:\/\/medscriptum.org\/en\/fda-approves-zidesamtinib-for-the-treatment-of-ros1-positive-non-small-cell-lung-cancer-nsclc\/","title":{"rendered":"FDA Approves Zidesamtinib for the Treatment of ROS1-Positive Non-Small Cell Lung Cancer (NSCLC)"},"content":{"rendered":"

The U.S. Food and Drug Administration (FDA) has officially approved the next-generation ROS1-selective inhibitor zidesamtinib (Jideytro) for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC). Locally advanced<\/em> refers to cancer that has grown beyond its original site and spread into nearby tissues or regional lymph nodes but has not yet disseminated to distant organs. The FDA-approved indication is intended for patients who have previously received at least one ROS1 kinase inhibitor. Notably, the regulatory agency completed the approval process nearly two months ahead of the anticipated review timeline, following the designation of zidesamtinib as a Breakthrough Therapy and an Orphan Drug.<\/p>\n

ROS1-positive non-small cell lung cancer represents a rare and molecularly distinct subtype of lung cancer, affecting approximately 50,000 people worldwide each year. This subtype develops as a result of an abnormal ROS1 gene rearrangement (fusion), which leads to the production of an oncogenic protein and uncontrolled proliferation of tumor cells. This genetic alteration is more frequently observed in relatively younger patients, particularly those in the 40\u201350-year age group, most of whom have never smoked or have only a limited history of tobacco exposure. Management of these patients requires a specialized therapeutic approach because they often receive targeted therapies over prolonged periods, making continuous monitoring of both treatment efficacy and drug tolerability essential.<\/p>\n

The next-generation agent zidesamtinib was specifically engineered to overcome limitations related to the efficacy and tolerability of first-generation ROS1 inhibitors. Its mechanism of action is based on three key clinical priorities: high target selectivity, effective inhibition of a broad spectrum of ROS1 resistance mutations, and the ability to penetrate the blood\u2013brain barrier, with the aim of achieving effective control of central nervous system (CNS) metastases.<\/p>\n

The FDA\u2019s decision was based on results from the ARROS-1 Phase I\/II clinical trial, which evaluated the efficacy of zidesamtinib in patients with advanced-stage ROS1-positive solid tumors. Solid tumors are malignant growths that form a mass of abnormal tissue and do not contain liquid spaces, distinguishing them from hematologic malignancies such as leukemia. In oncology, the term \u201cpositive\u201d generally indicates the presence of a specific biomarker, receptor, or genetic alteration relevant to tumor biology and treatment selection.<\/p>\n

The primary analysis included 117 patients with non-small cell lung cancer whose disease had progressed following prior treatment with ROS1 inhibitors.<\/p>\n

The study results demonstrated that treatment with zidesamtinib produced meaningful and durable clinical activity, including among patients who had previously undergone multiple lines of therapy. The objective response rate (ORR)\u2014a key endpoint in clinical trials that measures the proportion of patients whose tumors show a predefined reduction in size following treatment\u2014was 44%. The duration of response remained sustained, with 82% of responders maintaining a response at six months and 69% at twelve months. The drug also demonstrated substantial activity in patients harboring ROS1 resistance mutations and in those with central nervous system involvement.<\/p>\n

These findings represent an important advancement for patients whose treatment remains challenging due to the development of CNS metastases and resistance to existing therapies. In addition, the role of healthcare professionals, including physicians and nurses, is critical in monitoring patient status, providing education, and managing adverse events. The most frequently reported adverse reactions included edema, peripheral neuropathy, constipation, fatigue, and dyspnea. Early recognition and appropriate management of these adverse effects are essential for maintaining patients\u2019 quality of life during treatment.<\/p>\n

Source: www.oncnursingnews.com<\/a><\/strong><\/p>\n","protected":false},"excerpt":{"rendered":"

The U.S. Food and Drug Administration (FDA) has officially approved the next-generation ROS1-selective inhibitor zidesamtinib (Jideytro) for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC). Locally advanced refers to cancer that has grown beyond its original site and spread into nearby tissues or regional lymph nodes but […]<\/p>\n","protected":false},"author":29,"featured_media":22713,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[1594,1668],"tags":[1845,6493,6492,6490,6491],"class_list":["post-22714","post","type-post","status-publish","format-standard","has-post-thumbnail","category-news","category-pharmacy","tag-fda","tag-jideytro","tag-nsclc","tag-ros1-positive-non-small-cell-lung-cancer","tag-zidesamtinib"],"acf":[],"_links":{"self":[{"href":"https:\/\/medscriptum.org\/en\/wp-json\/wp\/v2\/posts\/22714","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medscriptum.org\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medscriptum.org\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medscriptum.org\/en\/wp-json\/wp\/v2\/users\/29"}],"replies":[{"embeddable":true,"href":"https:\/\/medscriptum.org\/en\/wp-json\/wp\/v2\/comments?post=22714"}],"version-history":[{"count":1,"href":"https:\/\/medscriptum.org\/en\/wp-json\/wp\/v2\/posts\/22714\/revisions"}],"predecessor-version":[{"id":22715,"href":"https:\/\/medscriptum.org\/en\/wp-json\/wp\/v2\/posts\/22714\/revisions\/22715"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medscriptum.org\/en\/wp-json\/wp\/v2\/media\/22713"}],"wp:attachment":[{"href":"https:\/\/medscriptum.org\/en\/wp-json\/wp\/v2\/media?parent=22714"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medscriptum.org\/en\/wp-json\/wp\/v2\/categories?post=22714"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medscriptum.org\/en\/wp-json\/wp\/v2\/tags?post=22714"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}